Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

Yun Qiu, Lakshmeswari Ravi, Hsing Jien Kung

研究成果: 雜誌貢獻文章

258 引文 斯高帕斯(Scopus)

摘要

Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.
原文英語
頁(從 - 到)83-85
頁數3
期刊Nature
393
發行號6680
DOIs
出版狀態已發佈 - 五月 7 1998
對外發佈Yes

ASJC Scopus subject areas

  • General

指紋 深入研究「Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells」主題。共同形成了獨特的指紋。

  • 引用此